Investigational Drug Details
Drug ID: Drug91 Drug Name: Diosmin CID: 5281613 DrugBank ID: DB08995 Modality: Small Molecule Groups: approved US Approved: NO Other Approved: YES Identifier:
NCT05626166
Molecular Formula: C28H32O15 Molecular Weight: 608.5 g/mol Isomeric SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O Synonyms: diosmin; 520-27-4; Barosmin; Diosmine; Flebosten; Diosmil; Tovene; Ven-Detrex; Diovenor; Buchu Resin Phase 0: 1 Phase 1: 5 Phase 2: 3 Phase 3: 14 Phase 4: 9 Description: Diosmin is a semisynthetic drug indicated for the treatment of venous disease. Diosmin is a flavone that can be found in the plant Teucrium gnaphalodes. Diosmin is available as a prescription medicine in several European countries, and is available as a nutritional supplement in the United States and the rest of Europe. It should be noted that clinical studies have been inconclusive and no articles have been published pertaining to its use in the treatment of vascular disease. When used in rats, diosmin has been effective at mitigating hyperglycaemia, and may also have antineurodegenerative properties.
Knowledge Graph
Associated Data
dtID CID Compound Name Gene ID Gene Name Species PubMed IDs Action
dt765
5281613
Diosmin
5429
POLH
Homo sapiens (human)
None
dt766
5281613
Diosmin
196
AHR
Homo sapiens (human)
14644660 Diosmin binds to and results in increased activity of AHR protein
dt767
5281613
Diosmin
596
BCL2
Mus musculus (house mouse)
32061149 Diosmin inhibits the reaction [benzo(a)pyrene results in decreased expression of BCL2 protein]
dt768
5281613
Diosmin
596
BCL2
Rattus norvegicus (Norway rat)
21477647 [diosmin co-treated with lipopolysaccharides] results in increased expression of BCL2 protein
dt769
5281613
Diosmin
836
CASP3
Mus musculus (house mouse)
32061149 Diosmin inhibits the reaction [benzo(a)pyrene results in increased cleavage of CASP3 protein]
dt770
5281613
Diosmin
836
CASP3
Rattus norvegicus (Norway rat)
23665045 Diosmin inhibits the reaction [2-acetylaminofluorene results in increased activity of CASP3 protein]
dt771
5281613
Diosmin
836
CASP3
Rattus norvegicus (Norway rat)
29187079 Diosmin inhibits the reaction [acetic acid results in increased expression of CASP3 protein]
dt772
5281613
Diosmin
836
CASP3
Rattus norvegicus (Norway rat)
21477647 Diosmin inhibits the reaction [lipopolysaccharides results in increased activity of CASP3 protein]
dt773
5281613
Diosmin
840
CASP7
Rattus norvegicus (Norway rat)
23665045 Diosmin inhibits the reaction [2-acetylaminofluorene results in increased activity of CASP7 protein]
dt774
5281613
Diosmin
842
CASP9
Rattus norvegicus (Norway rat)
23665045 Diosmin inhibits the reaction [2-acetylaminofluorene results in increased activity of CASP9 protein]
Phase 0: Exploratory trials to assess drug behavior in humansPhase 1: Safety trials to determine safe dosage rangePhase 2: Efficacy trials to evaluate therapeutic effectsPhase 3: Large-scale trials to confirm efficacy and safetyPhase 4: Post-marketing surveillance for long-term safety and efficacy
Trial ID Title Phase Status Sponsor Indications Interventions
NCT05626166
the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis
PHASE3
UNKNOWN
Tanta University
Ulcerative Colitis
DRUG: Placebo|DRUG: Diosmin
Details
Disease ID Disease Name Definition Category Related Drugs Mechanism
No data available
Strategy ID Therapeutic Strategy Synonyms Related Drugs Mechanism
No data available
Related Literature (2)
PMID: 40138774Year: 2025Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), is a chronic inflammatory disorder characterized by an unclear et…
PMID: 29187079Year: 2018Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) is a chronic inflammatory disease affecting colon. The primary symptoms of UC are diarrhoea with blood and mucus and sometime…
